Synaffix and Innovent Biologics expand ADC collaboration

Netherlands-based Synaffix, which was recently acquired by Swiss contract development and manufacturing organization (CDMO Lonza (SIX: LONN), said today it has expanded its licensing agreement with China’s Innovent Biologics (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases.

Building on the core value proposition of Synaffix ADC technology – to enable best-in-class efficacy and tolerability for antibody-drug conjugates (ADCs) – the expanded deal with Innovent focuses on at least one new ADC candidate.

This builds on a previous agreement signed in June 2021, which granted Innovent rights to deploy Synaffix’s ADC technologies on a target-specific, non-exclusive basis, including GlycoConnect, HydraSpace and one of its toxSYN linker-payloads, for a therapeutic molecule (Innovent R&D code: IBI343, a CLDN18.2 ADC) which has advanced to Phase I clinical development.